Cancer registries
czech english
Impact of Oncotype DX testing on treatment decisions
in patients with breast cancer in the Czech Republic
(decision impact study)

Impact of Oncotype DX testing on treatment decisions in breast cancer patients: a decision impact study

The Oncotype DX project is a new type of registry, which evaluates the impact of Oncotype DX® testing on treatment decisions in patients with breast cancer in the Czech Republic. The Oncotype DX® test is used for breast cancer cases with positive hormone receptors: based on the examination of 21 specific genes, the test can distinguish between patients which might benefit from chemotherapy, and those which would probably not benefit from it. This might spare patients the negative health and quality of life impact of unnecessary chemotherapy, and reduce the costs to society and the healthcare system. The individualised Recurrence Score® results assess the potential benefit of chemotherapy and the likelihood of distant breast cancer recurrence within 10 years after the diagnosis.

More information about the Oncotype DX® test is available at www.oncotypedx.com.

Project objectives

The main objective of the project is to describe whether the result of Oncotype DX® test actually affects the physician’s treatment recommendations and his/her confidence in the recommended treatment plan by evaluating:

  • actual changes in treatment recommendations,
  • changes in expressed level of confidence in treatment recommendations,
  • physicians’ perceptions regarding the influence of the assay result on their treatment recommendations.

The project is divided into two stages:

  1. a baseline questionnaire indicating the therapeutic strategy the patient would recommend to the patient based upon the available clinical and pathologic data,
  2. the follow-up questionnaire enquiring whether the results of the Oncotype DX® assay changed and/or reinforced the initial treatment recommendations.